share_log

Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-3i, LP(0%),3i Management LLC(0%), etc.

Transcode Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-3i, LP(0%),3i Management LLC(0%), etc.

Transcode Therapeutics | SC 13G/A：超過5%持股股東披露文件(修正)-3i, LP(0%),3i Management LLC(0%)等
美股SEC公告 ·  11/07 08:08

牛牛AI助理已提取核心訊息

Transcode Therapeutics, Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The filing, an Amendment No. 1 to Schedule 13G, indicates that the reporting persons, 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, have ceased to be the beneficial owners of more than five percent of the outstanding common stock of Transcode Therapeutics. This amendment serves as an exit filing for the reporting persons, effectively updating their beneficial ownership information and amending previous disclosures. The reporting persons have confirmed that their holdings are not for the purpose of changing or influencing the control of the issuer. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013.
Transcode Therapeutics, Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on September 30, 2024. The filing, an Amendment No. 1 to Schedule 13G, indicates that the reporting persons, 3i, LP, 3i Management LLC, and Maier Joshua Tarlow, have ceased to be the beneficial owners of more than five percent of the outstanding common stock of Transcode Therapeutics. This amendment serves as an exit filing for the reporting persons, effectively updating their beneficial ownership information and amending previous disclosures. The reporting persons have confirmed that their holdings are not for the purpose of changing or influencing the control of the issuer. The principal business address for all reporting persons is listed as 2 Wooster Street, 2nd Floor, New York, NY 10013.
Transcode Therapeutics, Inc.已經於2024年9月30日向美國證券交易委員會（SEC）提交了修正文件。這份修正文件是關於提交第13G表的修正案1，表明報告人3i，LP，3i Management LLC和Maier Joshua Tarlow已停止成爲Transcode Therapeutics未流通普通股超過5%的受益所有人。這份修正文件作爲報告人的退出申報，有效更新了他們的受益所有權信息並修改了先前的披露。報告人已確認其持股不是爲了改變或影響發行人的控制。所有報告人的主要業務地址均列爲紐約市10013號2 Wooster Street，2樓。
Transcode Therapeutics, Inc.已經於2024年9月30日向美國證券交易委員會（SEC）提交了修正文件。這份修正文件是關於提交第13G表的修正案1，表明報告人3i，LP，3i Management LLC和Maier Joshua Tarlow已停止成爲Transcode Therapeutics未流通普通股超過5%的受益所有人。這份修正文件作爲報告人的退出申報，有效更新了他們的受益所有權信息並修改了先前的披露。報告人已確認其持股不是爲了改變或影響發行人的控制。所有報告人的主要業務地址均列爲紐約市10013號2 Wooster Street，2樓。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間